SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Sol-Gel Technologies Ltd.
Date: May 2, 2025 · CIK: 0001684693 · Accession: 0000000000-25-004708

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286822

Date
May 2, 2025
Author
Division of
Form
UPLOAD
Company
Sol-Gel Technologies Ltd.

Letter

Re: Sol-Gel Technologies Ltd. Registration Statement on Form F-3 Filed April 29, 2025 File No. 333-286822 Dear Moshe Arkin:

May 2, 2025

Moshe Arkin Interim Chief Executive Officer Sol-Gel Technologies Ltd. 7 Golda Meir Street Weizmann Science Park Ness Ziona, 7403650, Israel

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jeffrey Schultz

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 2, 2025

Moshe Arkin
Interim Chief Executive Officer
Sol-Gel Technologies Ltd.
7 Golda Meir Street
Weizmann Science Park
Ness Ziona, 7403650, Israel

 Re: Sol-Gel Technologies Ltd.
 Registration Statement on Form F-3
 Filed April 29, 2025
 File No. 333-286822
Dear Moshe Arkin:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Lauren Hamill at 303-844-1008 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jeffrey Schultz
</TEXT>
</DOCUMENT>